The COSMYC Trial is a Phase 2 clinical trial investigating a novel sequential treatment strategy for men with metastatic castration-resistant prostate cancer (mCRPC).
This open-label study will evaluate if combining ZEN-3694, a BET inhibitor, with high-dose testosterone (BAT) can shrink tumors and delay progression in patients resistant to standard therapies. Upon progression on BAT and ZEN-3694 (BATZEN), patients will transition to a combination of a higher dose of ZEN-3694 and enzalutamide (ZENZA).
This approach targets MYC-driven pathways and aims to overcome resistance to androgen receptor inhibitors
The primary goals are to assess if BATZEN improves progression-free survival (PFS) and if ZENZA enhances PSA-progression-free survival.
The trial is expected to begin in June 2025 and conclude by June 2031, under the leadership of Dr Samuel Denmeade at Johns Hopkins.